IDEAYA Biosciences Q1 2026 Earnings: Revenue Context and Persistent Losses

IDEAYA Biosciences (IDYA) has just reported its Q1 2026 results, and investors are looking at them through the lens of a business that recently generated Q4 2025 revenue of US$10.9 million alongside a basic EPS loss of US$0.94 and a net loss of US$83.3 million. The company has seen quarterly revenue range from US$0 to US$207.8 million over the past year, with basic EPS swinging between a profit of US$1.35 and losses of up to US$1.49 per share, underscoring how tied the income statement is to the timing of revenue events. With revenue forecasts pointing higher but losses still material, the focus now is squarely on how much of that future top line can eventually translate into more resilient margins.

See our full analysis for IDEAYA Biosciences.

With the headline numbers in place, the next step is to compare these results with the widely followed narratives around IDEAYA's growth potential, risk profile, and path toward better margins to see which views align with the latest data and which are challenged by it.

Revenue Swings Around One-Off Deals

• Over the last six reported quarters, revenue has ranged from US$0 to US$207.8 million, with Q4 2025 at US$10.9 million and several quarters at US$0, which shows a heavy reliance on irregular revenue events rather than steady product sales.
• Bulls who focus on the 57.31% forecast revenue growth per year get some support from the trailing twelve month revenue of US$218.7 million. However, the fact that part of this comes from a single quarter at US$207.8 million means the growth story is closely tied to the timing and scale of individual agreements rather than a smooth revenue base.
  • Supporters often point to this US$218.7 million trailing figure versus earlier quarters with US$0 revenue as evidence that IDEAYA can sign sizable deals, which fits a growth-focused view.
  • At the same time, the pattern of US$0 revenue in multiple quarters shows why investors watching this bullish angle usually pay close attention to how repeatable those large contributions are.

Curious how others are interpreting these uneven revenue contributions against high growth forecasts, and what that might mean for IDEAYA over the long run, 📊 Read the what the Community is saying about IDEAYA Biosciences.

Losses Persist Despite Revenue Spike

• Across the last six reported quarters, IDEAYA has remained loss making, with quarterly net income excluding extra items ranging from a loss of US$72.2 million to US$130.3 million and only one profitable quarter at US$119.2 million, while trailing twelve month net loss sits at US$113.7 million even after that profitable period.
• Bears who focus on unprofitability highlight that losses have increased at about 40.8% per year over the past five years and forecasts indicate the company is not expected to be profitable over the next three years. This lines up with quarterly losses such as US$83.3 million in Q4 2025 and multiple quarters above US$70 million in red ink.
  • This pattern of sizeable losses alongside large but intermittent revenue, like US$207.8 million in Q3 2025, supports the cautious view that high revenue alone has not yet translated into a consistent path to positive earnings.
  • For that bearish stance, the key tension is that even as revenue forecasts look strong, the repeated losses suggest investors still need to see clear evidence that future revenue can cover ongoing costs.

Valuation Signals Pull In Different Directions

• At a share price of US$28.80, IDEAYA trades on a P/S of 11.6x compared with 10.8x for the broader US biotechs industry and 6.6x for its peer group, while the supplied DCF fair value of US$288.22 per share implies the stock is trading at roughly a tenth of that modeled level.
• What stands out for investors comparing bullish and cautious views is the tension between a relatively rich P/S multiple versus peers and a high DCF fair value. The model implies large upside while the P/S ratio suggests the stock is already priced more expensively on sales than many biotech peers.
  • Supporters of the higher DCF fair value often point to the 57.31% forecast revenue growth as a reason this long term model can produce a much higher number than the current US$28.80 price.
  • Critics counter that, given ongoing losses and no expected profitability over the next three years, a P/S above both industry and peer averages means investors are paying up for growth that still comes with meaningful earnings risk.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on IDEAYA Biosciences's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

The mix of optimism and concern across revenue, losses, and valuation makes this a polarising story. Check the full picture, weigh the trade offs, and ground your decision in the data by looking at the 2 key rewards and 1 important warning sign

See What Else Is Out There

IDEAYA's story combines irregular revenue, ongoing sizeable losses, and a P/S above industry and peer averages, which may leave you questioning the overall risk profile.

If that level of uncertainty feels uncomfortable, you can shift focus toward companies with steadier financial footing by checking out the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.